Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Robert Moore

Interventional Pain Medicine The Woodlands, TX Medical Doctor

NPI 1245241124 CMS profile 146717

9100 Forest Xing Ste A, The Woodlands, TX 77381

Open in the dashboard

General payments

$5,430

229 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Robert Moore of The Woodlands, TX is reported in the CMS Open Payments database as having received $5,430 across 229 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $37 2
2022 General $1,053 49
2021 General $1,396 66
2020 General $1,824 53
2019 General $1,121 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Moore
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Robert Moore were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Robert Moore Interventional Pain Medicine median Middle half National median
2019 $1,121 $684 $216–$2,079 $163
2020 $1,824 $382 $122–$1,109 $114
2021 $1,396 $552 $167–$1,554 $132
2022 $1,053 $605 $187–$1,924 $149
2023 $37 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Abbott Laboratories $2,120 56 payments
  2. Boston Scientific Corporation $680 28 payments
  3. Collegium Pharmaceutical, Inc. $447 33 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $268 17 payments
  5. Biodelivery Sciences International, Inc. $213 13 payments
  6. Nevro Corp. $140 1 payment
  7. GRT US Holding, Inc. $134 3 payments
  8. Amgen Inc. $122 5 payments
  9. Scilex Pharmaceuticals Inc. $117 7 payments
  10. Sentynl Therapeutics, Inc. $112 9 payments
  11. Other $1,078 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $4,375 227 payments
  2. Consulting Fee $1,050 1 payment
  3. Education $5 1 payment
Products named General payments · program years 2019–2023
  1. Axium Sheath Braided DRG $1,050 1 payment
  2. XTAMPZA $401 30 payments
  3. PROCLAIM $333 10 payments
  4. Superion Vertiflex Superion $291 5 payments
  5. RELISTOR $268 17 payments
  6. Proclaim IPG $189 14 payments
  7. SUPERION Pain Management $150 7 payments
  8. Neuromodulation Dspsbls and Accs $147 2 payments
  9. Proclaim Family of SCS IPGs $143 13 payments
  10. Omnia $140 1 payment
  11. Other $2,707 165 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

56

Median for Interventional Pain Management: 1,220

Drug cost

$1,020

Median for Interventional Pain Management: $39,344

Branded share of claims

100%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 56 $1,020

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Records

229 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record